Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Solomon

Showing results (1461-1470 of 1,873) with videos related to

Pageof 188
Sort By:
European Journal of Heart Failure|May 24, 2024
Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trialCarolyn S P Lam, Lars Køber, Koichiro Kuwahara, et al.
European Journal of Heart Failure|March 2, 2026
Mitral regurgitation in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HFMisato Chimura, Kieran F Docherty, Pardeep S Jhund, et al.
JACC. Heart Failure|October 13, 2023
Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF TrialMaria Pabon, Jon Cunningham, Brian Claggett, et al.
The American Journal of Cardiology|February 4, 2021
Soluble Angiotensin-Converting Enzyme 2, Cardiac Biomarkers, Structure, and Function, and Cardiovascular Events (from the Atherosclerosis Risk in Communities Study)Aliza Hussain, Olive Tang, Caroline Sun, et al.
European Journal of Heart Failure|February 17, 2021
Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trialJawad H Butt, Jose C Nicolau, Subodh Verma, et al.
JACC. Heart Failure|July 11, 2021
Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF TrialMauro Gori, Michele Senni, Brian Claggett, et al.
European Journal of Heart Failure|March 27, 2020
Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndromeSung-Hee Shin, Brian Claggett, Marc A Pfeffer, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 13, 2020
Cyclic peptides can engage a single binding pocket through highly divergent modesKarishma Patel, Louise J Walport, James L Walshe, et al.
JAMA Cardiology|November 13, 2020
Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With the Guidelines-Heart Failure (GWTG-HF) RegistryMuthiah Vaduganathan, Stephen J Greene, Shuaiqi Zhang, et al.
Nature Communications|September 18, 2020
A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severityAngkana T Huang, Bernardo Garcia-Carreras, Matt D T Hitchings, et al.
Pageof 188

Showing results (1461-1470 of 1,873) with videos related to

Sort By:
Pageof 188
European Journal of Heart Failure|May 24, 2024
Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trialCarolyn S P Lam, Lars Køber, Koichiro Kuwahara, et al.
European Journal of Heart Failure|March 2, 2026
Mitral regurgitation in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HFMisato Chimura, Kieran F Docherty, Pardeep S Jhund, et al.
JACC. Heart Failure|October 13, 2023
Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF TrialMaria Pabon, Jon Cunningham, Brian Claggett, et al.
The American Journal of Cardiology|February 4, 2021
Soluble Angiotensin-Converting Enzyme 2, Cardiac Biomarkers, Structure, and Function, and Cardiovascular Events (from the Atherosclerosis Risk in Communities Study)Aliza Hussain, Olive Tang, Caroline Sun, et al.
European Journal of Heart Failure|February 17, 2021
Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trialJawad H Butt, Jose C Nicolau, Subodh Verma, et al.
JACC. Heart Failure|July 11, 2021
Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF TrialMauro Gori, Michele Senni, Brian Claggett, et al.
European Journal of Heart Failure|March 27, 2020
Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndromeSung-Hee Shin, Brian Claggett, Marc A Pfeffer, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 13, 2020
Cyclic peptides can engage a single binding pocket through highly divergent modesKarishma Patel, Louise J Walport, James L Walshe, et al.
JAMA Cardiology|November 13, 2020
Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With the Guidelines-Heart Failure (GWTG-HF) RegistryMuthiah Vaduganathan, Stephen J Greene, Shuaiqi Zhang, et al.
Nature Communications|September 18, 2020
A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severityAngkana T Huang, Bernardo Garcia-Carreras, Matt D T Hitchings, et al.
Pageof 188